The global women’s health therapeutics market is likely to register a CAGR of over 5.4% with an incremental growth of USD 21 billion during the forecast period 2022-2028.

This industry report offers market estimates of the global market, followed by a detailed analysis of the indication, and region. The global market data on women’s health therapeutics can be segmented by indication: breast cancer, endometriosis, menopause, polycystic ovary syndrome (PCOS), postmenopausal osteoporosis. The breast cancer segment captured the largest share of the market in 2021. Women’s health therapeutics market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America held the largest share of the global women’s health therapeutics market in 2021 and is anticipated to hold its share during the forecast period.

The global women’s health therapeutics market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., The Bristol-Myers Squibb Company (BMS).

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
– Get a detailed picture of the Global Women’s Health Therapeutics Market
– Identify segments/areas to invest in over the forecast period in the Global Women’s Health Therapeutics Market
– Understand the competitive environment, the market’s leading players
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.